![Sandra Aung](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Sandra Aung is currently Chief Clinical Officer at Ambrx, Inc. since 2023.
Formerly, Dr. Aung was Chief Clinical Development Officer & Senior VP at OncoSec Medical, Inc. from 2020 to 2023.
Dr. Aung earned a doctorate from Vanderbilt University.
Ehemalige bekannte Positionen von Sandra Aung
| Unternehmen | Position | Ende |
|---|---|---|
| AMBRX INC | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2025 |
| ONCOSEC MEDICAL INCORPORATED | Corporate Officer/Principal | 01.01.2023 |
Ausbildung von Sandra Aung
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
24
Beziehungen ersten Grades
3
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
OncoSec Medical, Inc.
 OncoSec Medical, Inc. BiotechnologyHealth Technology Engages in discovery and development of novel immunotherapeutic products for immuno-oncology treatment | Health Technology |
Vanderbilt University
 Vanderbilt University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ambrx, Inc.
 Ambrx, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
